SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-215346
Filing Date
2020-08-11
Accepted
2020-08-10 21:48:03
Documents
15
Period of Report
2020-08-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d79922d8k.htm   iXBRL 8-K 46684
2 EX-2.1 d79922dex21.htm EX-2.1 608473
3 EX-99.1 d79922dex991.htm EX-99.1 122612
4 EX-99.2 d79922dex992.htm EX-99.2 77283
  Complete submission text file 0001193125-20-215346.txt   1164172

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20200810.xsd EX-101.SCH 3063
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20200810_lab.xml EX-101.LAB 18138
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20200810_pre.xml EX-101.PRE 11403
8 EXTRACTED XBRL INSTANCE DOCUMENT d79922d8k_htm.xml XML 3421
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 201090932
SIC: 2834 Pharmaceutical Preparations